Because of considering FLT3 as a promising therapeutic target for AML therapy, this leads to the discovery of various small-molecule FLT3 inhibitors, such as Midostaurin, Lestaurtinib, and Quizartinib [30]. This evidence concerns the gene FLT3 and acute myeloid leukemia.